Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $274,882.65 in Stock

by · The Cerbat Gem

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) General Counsel Jonathan Allan sold 8,785 shares of the business’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $31.29, for a total transaction of $274,882.65. Following the completion of the sale, the general counsel directly owned 15,809 shares of the company’s stock, valued at $494,663.61. This represents a 35.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jonathan Allan also recently made the following trade(s):

  • On Thursday, December 4th, Jonathan Allan sold 1,018 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.87, for a total transaction of $31,425.66.
  • On Wednesday, December 3rd, Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.65, for a total transaction of $70,249.80.
  • On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total transaction of $68,017.52.
  • On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The shares were sold at an average price of $25.07, for a total value of $250,700.00.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $30.87 on Monday. The business’s 50 day simple moving average is $29.03 and its 200 day simple moving average is $19.97. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $38.69. The company has a market capitalization of $1.76 billion, a P/E ratio of 46.07 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The company had revenue of $10.63 million for the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in STOK. Allspring Global Investments Holdings LLC bought a new position in Stoke Therapeutics in the 2nd quarter valued at approximately $402,000. Siren L.L.C. increased its holdings in shares of Stoke Therapeutics by 12.4% during the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company’s stock worth $14,945,000 after buying an additional 247,347 shares in the last quarter. Aviva PLC acquired a new position in shares of Stoke Therapeutics during the second quarter worth $499,000. KLP Kapitalforvaltning AS lifted its stake in shares of Stoke Therapeutics by 131.6% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company’s stock valued at $150,000 after acquiring an additional 7,500 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Stoke Therapeutics by 117.0% during the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company’s stock valued at $174,000 after acquiring an additional 14,118 shares in the last quarter.

Analysts Set New Price Targets

STOK has been the subject of several recent analyst reports. Chardan Capital raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. JPMorgan Chase & Co. boosted their target price on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday, December 1st. Wedbush lifted their price objective on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Finally, Canaccord Genuity Group boosted their price objective on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $31.00.

Get Our Latest Report on STOK

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Further Reading